CD8A and neoplasm: In mouse models, endothelial FASL limits T-cell infiltration, preferentially eliminating tumour-reactive CD8+ effector T-cells while sparing Tregs, skewing the CD8+/Foxp3+ T-cell ratio, and promoting immune tolerance and tumour progression [340].